Use of new psychoactive substances to mimic prescription drugs: The trend in France

被引:15
|
作者
Batisse, Anne [1 ]
Eiden, Celine [2 ]
Peyriere, Helene [2 ]
Djezzar, Samira [1 ]
机构
[1] GH Lariboisiere Fernand Widal, St Louis AP HP, Addictovigilance Ctr Paris, Paris, France
[2] Univ Hosp Montpellier, Addictovigilance Ctr Montpellier, Montpellier, France
关键词
Addiction; New psychoactive substances; Designer medecines; Health monitoring; ADDICTOVIGILANCE; ETHYLPHENIDATE; NETWORK;
D O I
10.1016/j.neuro.2020.03.015
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Among the expanding world of New Psychoactive Substances (NPS), Designer Medicines (DM) are designed to mimic psychoactive drugs and might lead to adverse events of various severity. The DM category includes designer benzodiazepines (DB), phenmetrazine, modafinil, methylphenidate analogs, and novel synthetic opioids (NSO). To investigate DM-related complications in France, all data on NPS collected in the French Addictovigilance network database through spontaneous reports (SRs) and the annual survey on deaths related to the abuse of licit and illicit psychoactive substances (DRAMES survey) between 2009 and 2017 were analyzed. From 2009-2017, about 800 cases of NPS-related abuse or somatic complications were reported to the French Addictovigilance Network, including 71 fatal cases (9%). DM use progressively increased over the years, particularly after 2013 (4% of all SRs on NPS in 2011 versus 14 % in 2017). Moreover, DM were implicated in 17 % of NPS-related deaths in France, just after cathinones (43 %) and dissociative drugs (22 %). NSO, DB and phenidate analogs were identified in 42 %, 25 % and 25 % of all DM-related death reports, respectively. DM seem to interest a new target group of users that includes mainly patients and healthy people rather than substance users. The availability on the Internet of compounds mimicking therapeutic drugs is a worrying phenomenon that could lead to their uncontrolled use.
引用
收藏
页码:20 / 24
页数:5
相关论文
共 50 条
  • [21] New psychoactive substances
    Davidson, Colin
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2012, 39 (02): : 219 - 220
  • [22] New psychoactive substances: Are there any good options for regulating new psychoactive substances?
    Reuter, Peter
    Pardo, Bryce
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2017, 40 : 117 - 122
  • [23] Non-medical use of psychoactive prescription drugs is associated with fatal poisoning
    Haukka, Jari
    Kriikku, Pirkko
    Mariottini, Claudia
    Partonen, Timo
    Ojanpera, Ilkka
    ADDICTION, 2018, 113 (03) : 464 - 472
  • [24] INCREASING USE OF PRESCRIPTION AND OVER-COUNTER PSYCHOACTIVE DRUGS BY ADULTS IN US
    BOE, S
    JOURNAL OF DRUG ISSUES, 1971, 1 (04) : 286 - 294
  • [25] New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon?
    Vidal Gine, Claudio
    Fornis Espinosa, Ivan
    Ventura Vilamala, Mireia
    DRUG TESTING AND ANALYSIS, 2014, 6 (7-8) : 819 - 824
  • [26] Fentanyl and its derivatives as a group of new psychoactive substances (designer drugs)
    Zawadzki, Marcin
    Nowak, Karolina
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2018, 72 : 547 - 556
  • [27] Psychoactive substances use among Tunisian adolescents: Trend analysis 2013-2021
    Zribi, M.
    Rejaibi, S.
    Zid, M.
    Silini, A.
    Zoghlami, N.
    Mallekh, R.
    Ben Slama, I.
    Ben Youssef, S.
    Ben Salah, N.
    Aounallah-Skhiri, H.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2023, 33
  • [28] The Use of Psychoactive Substances in Germany
    Rauschert, Christian
    Mockl, Justin
    Seitz, Nicki-Nils
    Wilms, Nicolas
    Olderbak, Sally
    Kraus, Ludwig
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2022, 119 (31-32): : 527 - +
  • [29] USE OF PSYCHOACTIVE SUBSTANCES BY RESIDENTS
    MADDUX, JF
    TIMMERMAN, IM
    COSTELLO, RM
    JOURNAL OF MEDICAL EDUCATION, 1987, 62 (10): : 852 - 854
  • [30] The Trend Points towards Pure Substances - Changes in the use of "Legal Highs"/New Psychoactive Substances (NPS) Based on the Results of 2 Online Surveys
    Werse, B.
    Morgenstern, C.
    SUCHTTHERAPIE, 2015, 16 (01) : 36 - 41